{
    "pmcid": "11057648",
    "qa_pairs": {
        "How do ESM models contribute to the design of SARS-CoV-2 nanobody binders?": [
            "By predicting and generating sequences that can potentially bind to viral proteins with high affinity",
            "By directly synthesizing nanobodies in the laboratory",
            "By providing structural models of viral proteins",
            "By identifying existing antibodies in natural libraries"
        ],
        "What is a challenge mentioned in using ESM for nanobody design?": [
            "The need for domain-specific data to fine-tune the models",
            "The inability to generate any new sequences",
            "The lack of computational resources to run the models",
            "The models' tendency to produce only known sequences"
        ],
        "What is one advantage of using ESM models in nanobody design?": [
            "They can generate diverse nanobody sequences not present in natural or synthetic libraries",
            "They can directly measure binding affinity in vitro",
            "They can replace the need for experimental validation",
            "They can automatically synthesize nanobodies"
        ],
        "What is the primary training corpus for ESM models like ESM-2?": [
            "UniRef corpus of protein sequences",
            "GenBank database of genetic sequences",
            "PDB database of protein structures",
            "Swiss-Prot database of annotated protein sequences"
        ],
        "Which machine learning techniques can be integrated with ESM to refine nanobody design?": [
            "Bayesian optimization and reinforcement learning",
            "Support vector machines and decision trees",
            "K-means clustering and hierarchical clustering",
            "Linear regression and logistic regression"
        ]
    }
}